Parkinson`s Disease Clinical Trial
Official title:
A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist
The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson`s disease.
1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than
levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison
of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment.
2. Prospective , randomized, open label study compare the onset time and severity of
dyskinesia between groups randomized assigned order of amantadine and dopamine agonist
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02224664 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease
|
Phase 1 | |
| Completed |
NCT01016470 -
Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson`s Disease
|
Phase 3 | |
| Unknown status |
NCT01313819 -
The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy
|
Phase 4 |